70 related articles for article (PubMed ID: 17549412)
21. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of an STI571-resistant human myelogenous leukemia cell line, SR-1.
Kwon HC; Kim SH; Kim JS; Han H; Roh MS; Han JY; Seo SY; Lee YH; Kim HJ
Cancer Genet Cytogenet; 2004 Oct; 154(1):52-6. PubMed ID: 15381372
[TBL] [Abstract][Full Text] [Related]
23. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
Breccia M; Frustaci AM; Cannella L; Soverini S; Stefanizzi C; Federico V; Grammatico S; Santopietro M; Alimena G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):195-7. PubMed ID: 19156415
[TBL] [Abstract][Full Text] [Related]
24. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
25. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
[TBL] [Abstract][Full Text] [Related]
26. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
27. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
28. The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines.
Timeus F; Crescenzio N; Ricotti E; Doria A; Bertin D; Saglio G; Tovo PA
Haematologica; 2006 May; 91(5):711-2. PubMed ID: 16670078
[TBL] [Abstract][Full Text] [Related]
29. Roots of imatinib resistance: a question of self-renewal?
Burchert A
Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
[TBL] [Abstract][Full Text] [Related]
30. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
31. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
33. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
[TBL] [Abstract][Full Text] [Related]
34. Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells.
Colavita I; Esposito N; Quintarelli C; Nigro E; Pane F; Ruoppolo M; Salvatore F
Proteomics; 2013 Aug; 13(16):2414-8. PubMed ID: 23754495
[TBL] [Abstract][Full Text] [Related]
35. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.
Bao F; Polk P; Nordberg ML; Veillon DM; Sun A; Deininger M; Murray D; Andersson BS; Munker R
Leuk Res; 2007 Nov; 31(11):1511-20. PubMed ID: 17403535
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia.
Burguillo FJ; Martin J; Barrera I; Bardsley WG
Comput Biol Chem; 2010 Jun; 34(3):184-92. PubMed ID: 20619742
[TBL] [Abstract][Full Text] [Related]
37. Synergistic and additive antiproliferative effects on human leukemia cell lines induced by combining acetylenehexacarbonyldicobalt complexes with the tyrosine kinase inhibitor imatinib.
Ott I; Abraham A; Schumacher P; Shorafa H; Gastl G; Gust R; Kircher B
J Inorg Biochem; 2006 Nov; 100(11):1903-6. PubMed ID: 16908070
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of a new human erythroleukemic cell line, ERY-1.
Ribadeau Dumas A; Hamouda NB; Leriche L; Piffaut MC; Bonnemye P; Kuen RL; Tricottet V; Merle-Beral H; N'Guyen Khac F; Arock M
Leuk Res; 2004 Dec; 28(12):1329-39. PubMed ID: 15475075
[TBL] [Abstract][Full Text] [Related]
39. Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.
Nemoto A; Inukai T; Uno K; Kiyokawa N; Miyagawa Y; Takahashi K; Sato H; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Nakazawa S; Fujimoto J; Inaba T; Sugita K
Leuk Res; 2013 Jan; 37(1):93-101. PubMed ID: 23099235
[TBL] [Abstract][Full Text] [Related]
40. Cancer drug resistance: the central role of the karyotype.
Duesberg P; Li R; Sachs R; Fabarius A; Upender MB; Hehlmann R
Drug Resist Updat; 2007; 10(1-2):51-8. PubMed ID: 17387035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
